Christiane E. Angermann

Christiane E. Angermann

Auto-generated profile, based on publicly available information

Christiane E. Angermann

Comprehensive Heart Failure Centre, University and University Hospital of Würzburg, Würzburg, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AVAdriaan A. Voors
Adriaan A. Voors
CAChristiane E. Angermann
Christiane E. Angermann
JTJohn R. Teerlink
John R. Teerlink
SCSean P. Collins
Sean P. Collins
MKMikhail Kosiborod
Mikhail Kosiborod
PPPiotr Ponikowski
Piotr Ponikowski
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days. The primary outcome of the trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90 days, as assessed using a win ratio. More patients treated with empagliflozin had clinical benefit compared with placebo (stratified win ratio, 1.36; 95% confidence interval, 1.09–1.68; P = 0.0054), meeting the primary endpoint. Clinical benefit was observed for both acute de novo and decompensated chronic heart failure and was observed regardless of ejection fraction or the presence or absence of diabetes. Empagliflozin was well tolerated; serious adverse events were reported in 32.3% and 43.6% of the empagliflozin- and placebo-treated patients, respectively. These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting treatment.

18 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JBJan Biegus
Jan Biegus
AVAdriaan A Voors
Adriaan A Voors
SCSean P Collins
Sean P Collins
MKMikhail N Kosiborod
Mikhail N Kosiborod
JTJohn R Teerlink
John R Teerlink
PPPiotr Ponikowski
Piotr Ponikowski
Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the EMPULSE trial (NCT0415775) were evaluated. A total of 530 patients hospitalized for AHF were randomized 1:1 to either empagliflozin 10 mg once daily or placebo for 90 days. The outcomes investigated were: weight loss (WL), WL adjusted for mean daily loop diuretic dose (WL-adjusted), area under the curve of change from baseline in N-terminal pro-B-type natriuretic peptide levels, hemoconcentration, and clinical congestion score after 15, 30, and 90 days of treatment. Compared with placebo, patients treated with empagliflozin demonstrated significantly greater reductions in all studied markers of decongestion at all time-points, adjusted mean differences (95% confidence interval) at Days 15, 30, and 90 were: for WL −1.97 (−2.86, −1.08), −1.74 (−2.73, −0.74); −1.53 (−2.75, −0.31) kg; for WL-adjusted: −2.31 (−3.77, −0.85), −2.79 (−5.03, −0.54), −3.18 (−6.08, −0.28) kg/40 mg furosemide i.v. or equivalent; respectively (all P < 0.05). Greater WL at Day 15 (i.e. above the median WL in the entire population) was associated with significantly higher probability for clinical benefit at Day 90 (hierarchical composite of all-cause death, heart failure events, and a 5-point or greater difference in Kansas City Cardiomyopathy Questionnaire total symptom score change from baseline to 90 days) with the win ratio of 1.75 (95% confidence interval 1.37, 2.23; P < 0.0001). Initiation of empagliflozin in patients hospitalized for AHF resulted in an early, effective and sustained decongestion which was associated with clinical benefit at Day 90. Empagliflozin in acute heart failure: the EMPULSE Trial. CI, confidence interval. Data shown for the treatment effect graphs are adjusted mean change from baseline, with error bars representing standard error. *The units of weight changes per mean daily loop diuretic dose are presented in kg/40 mg of intravenous furosemide (or 80 mg of oral furosemide) or equivalent. The equivalent to 40 mg of furosemide was defined as 20 mg of torasemide or 1 mg of bumetanide. †Measured as changes in haematocrit (%). ‡Calculated as a sum of the points allocated for dyspnoea, orthopnoea and fatigue. For each variable, a 0- to 3-point scale has been used, where points were allocated for: absence (0 points), seldom (1 point), frequent (2 points), and continuous (3 points) based on the frequency of the clinical sign. §The hierarchy and the components of the primary outcome measured by the win ratio: 1. Time to all-cause death; 2. Number of heart failure (HF) events (including hospitalizations for HFs, urgent HF visits and unplanned outpatient visits); 3. Time to first HF event; 4. ≥5 point difference in change from baseline in KCCQ total symptom score (KCCQ-TSS) after 90 days of treatment.

27 June 2020 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
CAChristiane E. Angermann
Christiane E. Angermann
BABirgit Assmus
Birgit Assmus
SAStefan D. Anker
Stefan D. Anker
FAFolkert W. Asselbergs
Folkert W. Asselbergs
JBJohannes Brachmann
Johannes Brachmann
MIMEMS‐HF Investigators
MEMS‐HF Investigators
Aims: Heart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP)-guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings have not been replicated in health systems outside the United States. Therefore, the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF) evaluated the safety, feasibility, and performance of this device in Germany, The Netherlands, and Ireland. Methods and results: A total of 234 NYHA class III patients (68 ± 11 years, 22% female, ≥1 HFH in the preceding year) from 31 centres were implanted with a CardioMEMS sensor and underwent PAP-guided HF management. One-year rates of freedom from device- or system-related complications and from sensor failure (co-primary outcomes) were 98.3% [95% confidence interval (CI) 95.8–100.0] and 99.6% (95% CI 97.6–100.0), respectively. Survival rate was 86.2%. For the 12 months post- vs. pre-implant, HFHs decreased by 62% (0.60 vs. 1.55 events/patient-year; hazard ratio 0.38, 95% CI 0.31–0.48; P < 0.0001). After 12 months, mean PAP decreased by 5.1 ± 7.4 mmHg, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall/clinical summary scores increased from 47.0 ± 24.0/51.2 ± 24.8 to 60.5 ± 24.3/62.4 ± 24.1 (P < 0.0001), and the 9-item Patient Health Questionnaire sum score improved from 8.7 ± 5.9 to 6.3 ± 5.1 (P < 0.0001). Conclusion: Haemodynamic-guided HF management proved feasible and safe in the health systems of Germany, The Netherlands, and Ireland. Physician-directed treatment modifications based on remotely obtained PAP values were associated with fewer HFH, sustainable PAP decreases, marked KCCQ improvements, and remission of depressive symptoms.

4 April 2022 in Circulation
Verified
Journal Article
Open access
PDF file
MKMikhail N. Kosiborod
Mikhail N. Kosiborod
CAChristiane E. Angermann
Christiane E. Angermann
SCSean P. Collins
Sean P. Collins
JTJohn R. Teerlink
John R. Teerlink
PPPiotr Ponikowski
Piotr Ponikowski
AVAdriaan A. Voors
Adriaan A. Voors
Background: Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chronic heart failure, but their effect on these outcomes in acute heart failure is not well characterized. We investigated the effects of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the EMPULSE trial (Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized). Methods: Patients hospitalized for acute heart failure were randomized to empagliflozin 10 mg daily or placebo for 90 days. The KCCQ was assessed at randomization and 15, 30, and 90 days. The effects of empagliflozin on the primary end point of clinical benefit (hierarchical composite of all-cause death, heart failure events, and a 5-point or greater difference in KCCQ Total Symptom Score [TSS] change from baseline to 90 days) were examined post hoc across the tertiles of baseline KCCQ-TSS. In prespecified analyses, changes (randomization to day 90) in KCCQ domains, including TSS, physical limitations, quality of life, clinical summary, and overall summary scores were evaluated using a repeated measures model. Results: In total, 530 patients were randomized (265 each arm). Baseline KCCQ-TSS was low overall (mean [SD], 40.8 [24.0] points). Empagliflozin-treated patients experienced greater clinical benefit across the range of KCCQ-TSS, with no treatment effect heterogeneity (win ratio [95% CIs] from lowest to highest tertile: 1.49 [1.01–2.20], 1.37 [0.94–1.99], and 1.48 [1.00–2.20], respectively; P for interaction=0.94). Beneficial effects of empagliflozin on health status were observed as early as 15 days and persisted through 90 days, at which point empagliflozin-treated patients experienced a greater improvement in KCCQ TSS, physical limitations, quality of life, clinical summary, and overall summary (placebo-adjusted mean differences [95% CI]: 4.45 [95% CI, 0.32–8.59], P =0.03; 4.80 [95% CI, 0.00–9.61], P =0.05; 4.66 [95% CI, 0.32–9.01], P =0.04; 4.85 [95% CI, 0.77–8.92], P =0.02; and 4.40 points [95% CI, 0.33–8.48], P =0.03, respectively). Conclusions: Initiation of empagliflozin in patients hospitalized for acute heart failure produced clinical benefit regardless of the degree of symptomatic impairment at baseline, and improved symptoms, physical limitations, and quality of life, with benefits seen as early as 15 days and maintained through 90 days. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT0415775.

2 March 2015 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
Gülmisal GüderGülmisal Güder
Gülmisal Güder
SSStefan Störk
Stefan Störk
GGGoetz Gelbrich
Goetz Gelbrich
SBSusanne Brenner
Susanne Brenner
NDNikolas Deubner
Nikolas Deubner
CAChristiane E. Angermann
Christiane E. Angermann

6 November 2018 in Current Heart Failure Reports
Verified
Journal Article
Closed access
PDF file
CAChristiane E. Angermann
Christiane E. Angermann
GEGeorg Ertl
Georg Ertl